The concurrence of hTERT promoter mutation and EGFR amplification has been confirmed in other studies.[4-6] However, controversial results exist regarding the association between hTERT promoter mutation and MGMT promoter methylation, IDH1/2 mutation, and 1p/19q deletion in primary glioblastomas.[5] [6] More evidence will be necessary to address this issue more confidently. The gene discussed is IDH1; the disease is glioblastoma.